Aspect Imaging Announces PhenoQuant(TM) Commercial Molecular Imaging Contrast Agent Program

June 29, 2011

CAGE Chemicals, University of Turin and Aspect Imaging to
Develop Applications and Products for Molecular Imaging on
Aspect’s M2(TM) Compact MRI System for Preclinical Imaging

TORONTO, Canada, SHOHAM, Israel, and TURIN, Italy, June 29, 2011 /PRNewswire/ -
Aspect Imaging today announced its agreement with CAGE Chemicals to
develop and manufacture Aspect’s PhenoQuant(TM) line of contrast agents for preclinical research. A third contributor in the
partnership, University of Turin’s Molecular Imaging Center under the
direction of Dr. Silvio Aime, will develop scientific pre-clinical
applications and protocols to support the use of the agents for
molecular imaging using Aspect’s M2(TM) compact high-performance MRI

Aspect Imaging has commercialized a novel MRI platform called the M2(TM)
that greatly simplifies the use and cost of MRI. As the system has no
magnetic fringe field and does not require the cost of dedicated
facilities or expert personnel associated with operating traditional
MRI systems, the M2 provides a significant advantage in terms of
affordability, ease of operation and flexibility of installation.
Another benefit of the M2 is the fact that its operating frequency – 1
Tesla – is optimal for performing contrast-enhanced molecular imaging
with gadolinium-based contrast agents. The arrangement with CAGE
Chemical to develop and commercialize PhenoQuant(TM) agents will enhance the breadth of applications that can be performed
on the M2 platform and will provide a wide variety of
application-specific agents.

“We are thrilled to announce the launch of our PhenoQuant(TM) contrast agent line and our partnership with CAGE Chemicals,” says Uri
Rapoport, Aspect Imaging’s Founder and CEO. “Our growing installed base
of leading research institutes using the M2 platform can now leverage
our new PhenoQuant(TM) agents to increase the breadth of biomarkers that can be quantified”.

“We are pleased to be working with Aspect Imaging to provide a broad
range of high quality molecular imaging agents to researchers worldwide
who are interested in phenotyping using the M2 compact MRI system”,
says Camilla Cavallotti, CEO of CAGE Chemicals. “CAGE’s excellence in
chemical synthesis, QC and manufacturing will ensure the highest levels
of quality and reproducibility required by leading molecular imaging

The first agent from the program will be a gadolinium-based MRI agent
for use with angiography and dynamic contrast imaging (DCE) on Aspect’s
M2 desktop MRI that will be used to assess changes in vascular
permeability in neo-formed vessels in tumor animal models. Forthcoming
agents will include those that can assess the over-expression and
up-regulation of receptors of folic acid involved in cancer, agents
that target specific integrin receptors, and agents that deal with
experiments of imaging-guided drug delivery.

PhenoQuant(TM) contrast agents will be distributed exclusively through Aspect Imaging
and optimized for use on Aspect’s M2 compact MRI system.

About Aspect Imaging:

Aspect Imaging (www.aspectimaging.com) is the world’s leader in high-performance compact MRI imaging systems
for preclinical, clinical and advanced industrial applications. In
preclinical research, Aspect’s M2(TM) platform and suite of products
enables academic researchers and pharmaceutical companies to harness
the power and insights of MRI but without the cost, complexity and
technical burden of traditional MRI systems. With Aspect’s integrated
and simple-to-use platform, researchers can derive deep insights into
their biological questions quickly, easily and cost-effectively – - and
all with the push of a button. As the system has no fringe magnetic
field, the M2 can be placed anywhere in a working lab including at a
scientist’s benchtop. The M2(TM) platform is used by leading institutions
for a broad range of in vivo, ex vivo and in vitro applications including high-resolution 3D anatomical, molecular, functional and
multi-modality imaging. The Aspect high-performance MRI system is used
to quantify the expression of disease, to monitor disease progression
and to assess therapeutic efficacy and response.

About CAGE Chemicals

CAGE Chemicals (www.cagechemicals.com) manufactures custom and catalogued specialty synthesized research
chemicals and imaging agents that combine biomedically relevant metal
irons and their delivery to customized biological targets. CAGE’s
strong expertise in synthetic chemistry, their focus on producing
commercial agents under the highest quality standards and their
extensive suite of analytical instruments ensure the highest levels of
reliable, reproducible and quality-based commercial molecular imaging
agents. CAGE is based on the established experience in the design,
synthesis and characterization of ligands and metal complexes for the
different techniques of molecular imaging. CAGE Chemicals is a spin-off
company originated in 2006 by researchers from the University of Turin
and the University of Eastern Piedmont.

SOURCE Aspect Imaging

Source: newswire

comments powered by Disqus